EU/3/14/1390: Orphan designation for the treatment of hereditary haemorrhagic telangiectasia
Table of contents
On 16 December 2014, orphan designation (EU/3/14/1390) was granted by the European Commission to Sophie Dupuis-Girod, France, for bevacizumab for the treatment of hereditary haemorrhagic telangiectasia.
Treatment of hereditary haemorrhagic telangiectasia
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
|December 2022||The sponsorship was transferred from Dr Sophie Dupuis-Girod, France to Laboratoires Delbert, France.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: